MK-0616 (Oral PCSK9 Inhibitor) Renal Impairment Study 2 (MK-0616-020)

Condition:   Hypercholesterolaemia Intervention:   Drug: MK-0616 Sponsor:   Merck Sharp & Dohme LLC Not yet recruiting

Source: ClinicalTrials.gov - July 6, 2023 Category: Research Source Type: clinical trials